SCHEDULE: T. Rowe Price Boosts Kenvue Stake to 8.8%

T. Rowe Price Associates, Inc. reported an increased beneficial ownership of Kenvue Inc. common stock, now holding 8.8% of the class.

Summary

• T. Rowe Price Associates, Inc. filed an Amendment No. 4 to its Schedule 13G for Kenvue Inc.
• The filing indicates T. Rowe Price beneficially owns 168,318,661 shares of Kenvue Inc. common stock.
• This ownership represents 8.8% of Kenvue Inc.'s outstanding common stock.
• T. Rowe Price holds sole voting power over 158,120,414 shares and sole dispositive power over 168,041,407 shares.
• The securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Kenvue Inc.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

This filing reflects a significant institutional investment in Kenvue Inc., a major player in the consumer health sector, by a prominent asset manager. Such large passive stakes by investment advisers are common and indicate a long-term investment strategy rather than an activist position.

Stakeholder Impact

• Shareholders: Provides transparency on a significant institutional holder's stake, confirming a large, passive investment.

Key Dates

Keywords

Kenvue Inc., T. Rowe Price, Beneficial Ownership, Common Stock, Institutional Investor, Consumer Health, SEC Filing, Schedule 13G